Antimicrobial susceptibility testing

MICRONAUT-S MRSA/GP

Phenotypic detection of clinically relevant single or multi-resistance in staphylococci, enterococci and streptococci organisms with highly effective backup antibiotics

Phenotypic resistance detection amongst gram-positive pathogens

In recent years there has been an increase in multi-drug resistance (MDR) amongst gram-positive pathogens. This has impacted both hospital and community acquired infections.

 

The MICRONAUT-S plates are designed to provide the routine laboratory with an efficient tool for phenotypic detection of the important resistance mechanisms among these bacteria. The MICRONAUT-S MRSA/GP also includes highly effective backup antibiotics: ceftaroline, daptomycin, linezolid, tigecycline, vancomycin, and teicoplanin.

Susceptibility Testing

The susceptibility testing is based on the rehydration of antibiotics by adding a standar­dized bacteria suspension (Mueller Hinton Broth, cation adjusted (CAMHB)). The result is measured photometri­cally after 18-24 hours incubation at 35-37°C. Results are measured and interpreted either with the MICRONAUT software or visually.

Due to a special vacuum drying method, the plates can be stored at a room temperature of 15-25°C. The MICRONAUT test plates have a shelf life of 24 months at date of production.

Antibiotic configuration for the detection of single or multi-resistances of gram-positive bacteria in nosocomial infections

The antibiotics configuration of the MICRONAUT-S MRSA/GP plate allows the specific detection of the clinically relevant single or multi-resistances of gram-positive bacteria in nosocomial infections.

The susceptibility testing with highly effective reserve antibiotics like ceftaroline offers the user alternatives in case of extreme multi-resistance. The MICRONAUT-S MRSA/GP offers the following features and benefits.

Susceptibility testing of Staphylococci

  • Penicillin G MIC: detection of staphylococcal penicillinases
  • Detection of MRSA resistance phenotype by MIC determination of oxacillin and cefoxitin
  • Detection of oxacillin borderline resistance phenotype (BORSA) by detection of cefoxitin susceptibility
  • Detection of the induced MLSB resistance by erythromycin/clindamycin combination test according to CLSI standard
  • Testing of highly effective antibiotics like vancomycin, linezolid, tigecycline, daptomycin and ceftaroline as therapeutic options in case of extreme multi-resistance
  • Test interpretation according to EUCAST and CLSI standard

Susceptibility testing of Enterococci

  • Ampicillin MIC: detection of ampicillin resistance
  • Detection of the phenotypic glycopeptide resistance pattern of vancomycin resistant Enterococci by determination of the MIC via teicoplanin and vancomycin
  • Differentiation between Enterococcus faecium and Enterococcus faecalis by determination of the MIC via Synercid®
  • Detection of HLAR strains through high-level-resistance testing via gentamicin and streptomycin
  • Testing of highly effective antibiotics as therapeutic options in case of extreme multi-resistance
  • Test interpretation according to EUCAST and CLSI standard

Susceptibility testing of Pneumococci

  • Penicillin G MIC: detection of PBP changes
  • Detection of cefotaxim resistance
  • Detection of erythromycin resistance
  • Detection of vancomycin resistance
  • Moxifloxacin MIC: detection of group IV quinolones resistance
  • Test of highly effective antibiotics as therapeutic options in case of extreme multi-resistance
  • Test interpretation according to EUCAST and CLSI standard

 

 

 

Please contact your local representative for availability in your country.

Not for sale in the USA.

Related products